fashion -WSS

fashion

author：entertainment 2025-09-28 23:31:04 - browse：71784

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Kaiser Permanente unions announce official strike date

WSS

How one patient went off dialysis — and others can too

Menendez indictment could see pharma lose a key ally

How one patient went off dialysis — and others can too

Emergency medicine has repudiated 'excited delirium.' Now what?

Meta's Zuckerberg and Chan on track to put $50 billion into science

Why Sanofi got shellacked over its spinoff

focus

fashion

focus

In age of alternative facts, a scholarly course on calling out crap

Physician subsidies by hospitals soar in wake of No Surprises Act

Medical leaders decry Supreme Court decision on affirmative action

Covid vaccines: Private market messier than government rollout

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Novavax promises a turnaround & Lilly roils the obesity market

Medicare drug price negotiation program allowed for now

As demand for Covid shots wanes, Moderna seeks its next success

Medicare drug price negotiation program allowed for now

entertainment

First Opinion Podcast: How to protect health care in times of war

Data show record exodus of life scientists from academia

Why Sanofi got shellacked over its spinoff

Kaiser Permanente unions announce official strike date

Shingles, which affected Dianne Feinstein, is on the rise

Physician subsidies by hospitals soar in wake of No Surprises Act

leisure time

hotspot

focus

knowledge